

Supplementary Table 1: Clinical characteristics of untreated patients with Parkinson's disease classified by low- and high-SCOPA-AUT score groups

	Untreated PD (n=32)	Low-SCOPA- AUT (<9)	High-SCOPA- AUT (≥ 9)	p-value
Age (years)	69.4 \pm 9.7	68.5 \pm 11.2	70.5 \pm 7.8	0.58
Sex (M/F)	13/19	7/10	6/9	0.95
Body mass index (kg/m ²)	22.7 \pm 5.2	21.3 \pm 6.2	24.3 \pm 3.6	0.12
Disease duration (years)	2.2 \pm 2.5	3.0 \pm 3.2	1.5 \pm 1.3	0.11
MMSE	26.8 \pm 3.7	27.4 \pm 2.8	26.1 \pm 4.4	0.44
Hoehn and Yahr stage	2.6 \pm 1.0	2.6 \pm 1.0	2.6 \pm 1.2	0.87
MDS-UPDRS III	28.9 \pm 14.9	31.7 \pm 15.0	26.1 \pm 14.8	0.32
MDS-UPDRS IV	0	0	0	-
LED (mg/day)	0	0	0	-
SCOPA-AUT total	8.5 \pm 6.0	4.2 \pm 2.8	13.4 \pm 4.8	<0.001
PDSS-2	10.6 \pm 6.2	8.1 \pm 5.1	13.2 \pm 6.3	0.021
ESS	6.5 \pm 5.6	4.8 \pm 4.1	8.1 \pm 6.5	0.12
BDI-II	11.2 \pm 8.5	7.3 \pm 7.0	15.3 \pm 8.2	0.011
RBDSQ-J	1.9 \pm 2.6	1.4 \pm 2.4	2.3 \pm 2.7	0.35
NMSS	32.1 \pm 18.1	16.7 \pm 13.7	51.2 \pm 31.6	0.0022
Non-autonomic NMSS	17.2 \pm 18.1	7.6 \pm 8.0	29.1 \pm 20.2	0.0026
DAT SPECT (average)	4.5 \pm 1.1	4.7 \pm 1.3	4.3 \pm 0.8	0.34
MIBG cardiac scintigraphy (delayed image)	2.1 \pm 1.0	2.3 \pm 1.1	1.8 \pm 0.8	0.22
Open essence*	4.0 \pm 2.4	3.7 \pm 2.7	4.2 \pm 2.1	0.55

MMSE=Mini-Mental State Examination; MDS-UPDRS=Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale; LED=levodopa equivalent dose; SCOPA-AUT=Scales for Outcomes in PD Autonomic; PDSS-2=PD sleep evaluation scale-2; ESS=Epworth sleepiness scale; BDI-II=Beck's depression inventory II; RBDSQ-J=RBD screening questionnaire, Japanese version; NMSS=Non-Motor Symptom Scale for PD; DAT SPECT=dopamine transporter (¹²³I FP-CIT) SPECT; MIBG=¹²³I-metaiodobenzylguanidine

*Open essence; olfactory function test

Supplementary Table 2: Correlation between the SCOPA-AUT and clinical parameters in untreated PD patients

SCOPA-AUT total		
	Correlation coefficient	p-value
Age	0.152	0.42
Body mass index	0.266	0.16
Disease duration	-0.043	0.82
MMSE	-0.161	0.50
Hoehn and Yahr stage	0.069	0.72
MDS-UPDRS III	-0.111	0.56
MDS-UPDRS IV	-	-
Levodopa equivalent dose	-	-
PDSS-2	0.454	0.012
ESS	0.235	0.22
BDI-II	0.641	<0.001
RBDSQ-J	0.240	0.21
NMSS	0.683	<0.001
Non-autonomic NMSS	0.688	<0.001
DAT scan (average)	-0.301	0.12
MIBG cardiac scintigraphy (delayed image)	-0.096	0.61
Open essence	-0.084	0.66

MMSE=Mini-Mental State Examination; MDS-UPDRS=Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale; LED=levodopa equivalent dose; SCOPA-AUT=Scales for Outcomes in PD Autonomic; PDSS-2=PD sleep evaluation scale-2; ESS=Epworth sleepiness scale; BDI-II=Beck's depression inventory II; RBDSQ-J=RBD screening questionnaire, Japanese version; NMSS=Non-Motor Symptom Scale for PD; DAT SPECT=dopamine transporter (^{123}I FP-CIT) SPECT; MIBG= ^{123}I -metaiodobenzylguanidine

*Open essence; olfactory function test